BioCentury | Oct 3, 2011
Finance

Value verification

...Ltd. (ASX:CUV; Xetra:UR9) Scenesse afamelanotide Prevent erythropoietic protoporphyria Submit MAA 4Q11 Cornerstone Therapeutics Inc. (NASDAQ:CRTX) CRTX 067...
BioCentury | Aug 8, 2011
Finance

Value vaporization

...product availability." R&D expenses fell 66% to $614,000, mainly due to decreased expenses related to CRTX 067...
BioCentury | Jul 20, 2009
Clinical News

CRTX 067 regulatory update

...treat cough. CRTX 067 is an extended-release anti-tussive agent. Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Product: CRTX 067...
BioCentury | Sep 22, 2008
Company News

Covidien Ltd. sales and marketing update

...Covidien launched TussiCaps extended-release hydrocodone/chlorpheniramine capsules in the U.S. to relieve cold-related cough. The price is...
Items per page:
1 - 4 of 4